Clearmind Medicine Inc. SEC Filings

Clearmind Medicine Inc. (CMND), a clinical-stage biopharmaceutical company, reports a key intellectual property milestone with U.S. publication of its patent application covering a novel combination of MDMA and N-acylethanolamines, such as palmitoylethanolamide (PEA), for treating PTSD, anxiety, and eating disorders. The application, published by the USPTO, arises from Clearmind’s collaboration with NeuroThera Labs Inc., which has already generated thirteen related patent applications globally. The new filing describes embodiments where PEA may enhance MDMA’s therapeutic potency, reduce required dosing, mitigate MDMA-associated side effects, and broaden its therapeutic window. Clearmind notes that this development aligns with growing U.S. federal focus on psychedelic medicines, including the FDA’s July 13, 2026 final guidance on clinical investigation of psychedelic drugs, which explicitly includes MDMA. Clearmind states that its overall IP portfolio now consists of nineteen patent families and 32 granted patents.

Clearmind Medicine Inc. has an updated Schedule 13G/A reporting the beneficial ownership of common shares by Iroquois Capital Management LLC, Richard Abbe, and Kimberly Page. The securities consist entirely of warrants to acquire common shares, rather than currently outstanding shares owned outright.

Iroquois Master Fund holds Reported Warrants to purchase 178,667 common shares, and Iroquois Capital Investment Group LLC holds Reported Warrants to purchase 168,000 common shares. Richard Abbe may be deemed to beneficially own 346,667 common shares issuable upon exercise of these warrants, while Iroquois Capital Management LLC and Kimberly Page may each be deemed to beneficially own 178,667 common shares issuable upon warrant exercise.

The filing states that each Reporting Person’s beneficial ownership is limited by contractual “Blockers,” which generally prevent exercise of the warrants to the extent it would result in beneficial ownership above 9.99% of Clearmind’s 1,485,551 common shares outstanding as of June 15, 2026, with certain warrants instead subject to a 4.99% cap.

Clearmind Medicine Inc. reported new permeation study data for its proprietary intranasal MEAI (5-Methoxy-2-aminoindane) formulation, part of its program targeting mental-health and metabolic disorders. The study compared intranasal MEAI with a conventional MEAI solution using Franz diffusion cells under physiologically relevant conditions.

Both formulations showed rapid, extensive permeation, with near-complete transport by 180 minutes: 97.35% cumulative permeation for intranasal MEAI versus 98.34% for the conventional solution. This suggests that the formulation’s previously demonstrated enhanced nasal residence time does not materially impair drug transport. Combined with prior ex vivo mucoadhesion data showing substantially longer association with nasal tissue, the company states that these results support continued development of intranasal MEAI as a differentiated therapeutic candidate for conditions such as alcohol use disorder, weight management, obesity, and metabolic diseases. Clearmind also highlights an intellectual property portfolio of nineteen patent families, including 32 granted patents.

Clearmind Medicine Inc. reports a key milestone in its CMND-100 program for Alcohol Use Disorder (AUD) after its independent Data and Safety Monitoring Board (DSMB) unanimously approved advancing an ongoing FDA-regulated Phase I/II trial to Parts B and C. Part A, conducted in healthy participants, met its primary safety endpoint, with CMND-100 showing a favorable safety and tolerability profile across all planned dose levels.

Part B will, for the first time, evaluate CMND-100 in human patients with moderate to severe AUD in two sequential cohorts of six patients each at 80 mg and 160 mg doses, assessing safety, tolerability and early signals of clinical activity, including potential reductions in alcohol consumption and craving. Part C will run concurrently in healthy participants at a fixed 160 mg daily dose over five consecutive days in a double-blind, placebo-controlled design to further characterize safety and tolerability.

The multicenter trial, focused on safety, tolerability, pharmacokinetics and preliminary efficacy in AUD, is being conducted at Johns Hopkins University, Yale School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center. Clearmind describes CMND-100 as a proprietary, non-hallucinogenic neuroplastogen-derived oral formulation and notes an intellectual property portfolio of nineteen patent families, including 32 granted patents.

Clearmind Medicine Inc. entered into a non-binding Letter of Intent to acquire a 51% majority stake in a company that provides intelligent wireless charging solutions for electric vehicles in automated parking systems and autonomous mobile platforms.

Under the LOI, Clearmind will acquire this stake for an aggregate purchase price of $2.5 million. As a condition to closing, Clearmind will extend a $1.5 million loan to the target company, bearing 4% annual interest and repayable two years after closing. Completion is subject to definitive agreements, final due diligence and other closing conditions. Clearmind remains primarily a clinical-stage biotech focused on non-hallucinogenic, neuroplastogen-derived therapeutics and holds nineteen patent families, including 32 granted patents.

Clearmind Medicine Inc. reported positive safety results from Part A of its FDA-regulated Phase I/II trial of CMND-100, an MEAI-based, non-hallucinogenic oral candidate for Alcohol Use Disorder. All 24 healthy volunteers across four ascending-dose cohorts completed treatment per protocol, and the primary safety and tolerability endpoint was achieved.

CMND-100 showed a consistent safety profile up to the highest tested dose of 160 mg, with no serious adverse events observed and strong overall tolerability. The company, assuming continued favorable findings from Part A, intends to progress the clinical program to subsequent stages, including dosing patients with Alcohol Use Disorder.

Clearmind Medicine Inc., a clinical-stage biotech focused on non-hallucinogenic neuroplastogen-derived treatments, has filed a patent application with the Hong Kong Patent Office for psychedelic-based compounds targeting Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. The application is part of an exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, under which Clearmind holds global rights to develop, manufacture, and commercialize novel compounds developed at Yissum.

The company states that Hong Kong patent protection supports access to the Asian market and complements existing patent coverage in the United States, Europe, and other regions. Clearmind reports an intellectual property portfolio of 19 patent families, including 32 granted patents, and views this filing as further expansion of its global IP position in large markets such as PTSD, which is cited as a multi‑billion‑dollar therapeutic opportunity.

Clearmind Medicine Inc., a clinical-stage psychedelic biotech, notes recent U.S. federal regulatory and inter-agency actions supporting development of psychedelic-based treatments for serious neuropsychiatric and addiction disorders.

The company develops novel, non-hallucinogenic, next-generation neuroplastogen-derived therapeutics, led by CMND-100 (MEAI / 5-MeO-AI), a non-hallucinogenic compound in FDA-cleared Phase I/IIa clinical trials for Alcohol Use Disorder at leading institutions including Yale University and Johns Hopkins.

Clearmind reports an intellectual property portfolio of nineteen patent families, including 32 granted patents, and aims to commercialize psychedelic-based compounds as regulated medicines, foods, or supplements. Its shares trade on Nasdaq under the symbol CMND.

Clearmind Medicine Inc., a clinical-stage biotechnology company focused on non-hallucinogenic neuroplastogen-derived treatments for alcohol use disorder, addiction and weight management, reported ex vivo mucoadhesion data showing its intranasal MEAI formulation maintained greater nasal tissue retention than a standard MEAI solution over a 30-minute evaluation.

The company explains that enhanced nasal residence is important because longer contact with nasal mucosa can increase absorption and therapeutic potential, supporting its intranasal MEAI program aimed at overcoming rapid mucociliary clearance. Clearmind also highlights a portfolio of nineteen patent families, including 32 granted patents, underpinning its neuroplastogen platform.